可注射水凝胶在慢性心力衰竭治疗中的前景与挑战
The prospect and challenges of injectable hydrogel in the treatment of chronic heart failure
李树成 1郭炳辰 1高殿钰 1王博 1涂应锋1
作者信息
- 1. 哈尔滨医科大学附属第一医院心血管内科,黑龙江哈尔滨 150001
- 折叠
摘要
心力衰竭是心血管疾病最主要的死亡原因,也是大多数心血管疾病的终末共同表现,全球约超过六千万人深受其影响.心脏移植目前仍是心力衰竭患者的治疗"金标准",心力衰竭患者在遵循基础药物治疗的情况下可以改善生活质量,延长生存时间.但由于心力衰竭的复杂机制以及众多并发症,常规的心力衰竭治疗策略在临床工作中的局限性被逐渐放大.近年来,介入治疗作为一种新兴的心力衰竭的治疗手段,受到人们的关注并取得重大突破,为心力衰竭患者带来新的希望.其中,可注射水凝胶由于其微创性和有效输送治疗药物的能力,在生物医学领域的应用受到了极大的关注.在慢性心力衰竭领域,可注射水凝胶主要应用于组织再生、药物输送和免疫治疗等.本文主要阐述可注射水凝胶在心力衰竭治疗领域的应用及研究进展.
Abstract
Heart failure is the leading cause of mortality in cardiovascular diseases and represents the ultimate common manifestation of most cardiovascular conditions,impacting over 60 million individuals globally.Currently,heart transplantation remains the standard treatment for heart failure patients.Adherence to fundamental pharmacotherapy can improve quality of life and extend survival time for heart failure patients.However,due to the complex mechanism of heart failure and numerous complications,the limitations of conventional heart failure treatment strategies in clinical work are gradually magnified.In recent years,interventional therapy has emerged as an innovative approach for managing heart failure,attracting significant attention and achieving substantial breakthroughs that offer new hope for affected individuals.Injectable hydrogel has garnered considerable interest in biomedicine due to its minimally invasive nature and capacity for efficient therapeutic drug delivery.In the context of chronic heart failure,injectable hydrogel finds application primarily in tissue regeneration,drug delivery,and immunotherapy.This review mainly describes the application and research progress of injectable hydrogel in the treatment of heart failure.
关键词
心力衰竭/介入治疗/可注射水凝胶Key words
Heart failure/Interventional strategy/Injectable hydrogel引用本文复制引用
基金项目
哈尔滨医科大学附属第一医院科研创新基金(2024M32)
出版年
2024
NETL
NSTL
万方数据